Neoadjuvant Chemoimmunotherapy

0

Pipeline Programs↗

6

Active Trials↗

0

Companies Involved↗

Neoadjuvant Chemoimmunotherapy is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

15/100

Mech. Concentration

N/A

Completion Rate

100/100

Attrition Rate

0/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

7

clinical trials

Recruiting4 · 57%

Not yet recruiting2 · 29%

Completed1 · 14%

Clinical Trials

Trial Activity

7 trials

TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC Without pCR After Neoadjuvant Chemoimmunotherapy

Recruiting·TTianjin Medical University Cancer Institute and Hospital·Phase 2·NCT07330037·41 enrolled

A Study Comparing Neoadjuvant Chemoimmunotherapy and Immuno-consolidationafter Compared With Immunoconsolidation After Radical Chemoradiotherapy for Stage III Potentially Resectable NSCLC

Recruiting·—·Phase 2·NCT06424899·92 enrolled

Neoadjuvant Chemoimmunotherapy Followed By Radiation Or Organ Preservation Surgery In Laryngeal/Hypopharyngeal Cancer

Recruiting·FFudan University·Phase 2·NCT06039631·82 enrolled

Neoadjuvant Chemoimmunotherapy Versus Concurrent Chemoradiotherapy for LACC

Recruiting·TTongji Hospital·Phase 2/3·NCT06288373·440 enrolled

Lingual Nerve Disruption to Augment Neoadjuvant Chemoimmunotherapy in Locally Advanced Tongue Cancer

Not yet recruiting·SShanghai Zhongshan Hospital·Phase 2·NCT07346807·69 enrolled

Neoadjuvant Chemoimmunotherapy (Camrelizumab + Paclitaxel + Carboplatin) for Resectable HNSCC

Not yet recruiting·National Medical Research Radiological Centre of the Ministry of Health of Russia·Phase 2·NCT07400094·50 enrolled

Response to Neoadjuvant Chemoimmunotherapy in Resectable Locally Advanced Oral Cancer

Completed·SSun Yat-Sen Memorial Hospital of Sun Yat-Sen University·N/A·NCT06143761·206 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)